Recent Quotes
My Watchlist
Indicators
Markets
Stocks
ETFs
Tools
Overview
News
Currencies
International
Treasuries

Nls Pharmaceutics Ltd (NQ: NLSP )

1.400 -0.010 (-0.71%)
Streaming Delayed Price Updated: 3:57 PM EST, Jan 30, 2023 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 50,453
Open 1.450
Bid (Size) 1.370 (2)
Ask (Size) 1.550 (7)
Prev. Close 1.410
Today's Range 1.400 - 1.480
52wk Range 0.3300 - 1.880
Shares Outstanding N/A
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
NLS Pharmaceutics Announces Completion of Open Label Extension Study with Quilience(R) (Mazindol ER) for the Treatment of Narcolepsy
Via ACCESSWIRE
NLS Pharmaceutics Regains Compliance with Nasdaq Stockholders' Equity Requirement
Via ACCESSWIRE

Performance

YTD
N/A
N/A
1 Month
N/A
N/A
3 Month
+167.94%
+167.94%
6 Month
+278.28%
+278.28%
1 Year
+55.56%
+55.56%

More News

Read More
NLS Pharmaceutics Announces New In-Vitro Data Reconfirming Quilience's(R) (Mazindol ER) Unique Dual Mechanism of Action Involving Significant Orexin-2 Receptor Activity
Via ACCESSWIRE
NLS Pharmaceutics Announces an R&D Update Webcast to Review the Company's Growing Portfolio of Pre-Clinical Compounds
Via ACCESSWIRE
NLS Pharmaceutics Announces Purchase Agreement with BVF Partners L.P. to Raise Aggregate Gross Proceeds of up to $30 Million
Via ACCESSWIRE
Why Calyxt Shares Are Trading Higher By Around 116%? Here Are Other Stocks Moving In Tuesday's Mid-Day Session
Via Benzinga
NLS Pharmaceutics Announces Compliance with Nasdaq Bid Price Requirement
Via ACCESSWIRE
NLS Pharmaceutics to Participate in Upcoming Investor Conferences
Via ACCESSWIRE
NLS Pharmaceutics Announces Technology Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Rare Sleep Disorders in Hong Kong
Via ACCESSWIRE
NLS Pharmaceutics CEO Issues Letter to Shareholders
Via ACCESSWIRE
NLS Pharmaceutics Announces Israeli Patent Grant Covering Mazindol for Treatment of Attention Deficit Hyperactivity Disorder and Other Sleep Disorders Through 2037
Via ACCESSWIRE
NLS Pharmaceutics Announces Closing of Initial Tranche of US$10.0 Million Purchase Agreement with BVF Partners L.P.
Via ACCESSWIRE
NLS Pharmaceutics Announces Receipt of Nasdaq Minimum Bid Price Notification
Via ACCESSWIRE
NLS Pharmaceutics Announces Notice of Allowance for U.S. Patent Covering Mazindol for Opioid Dependence and Substance Use Disorder
Via ACCESSWIRE
Why Canoo Shares Are Trading Higher By Over 12%? Here Are 32 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Richardson Electronics Shares Surged Over 8%; Here Are 55 Biggest Movers From Friday
Via Benzinga
NLS Pharmaceutics Announces Launch of Paid for Named Patient Program with Mazindol ER for Idiopathic Hypersomnia, a Serious Sleep Disorder with No Approved Treatment Options in Europe
Via ACCESSWIRE
Why Coupa Software Shares Jumped Around 29%; Here Are 72 Biggest Movers From Wednesday
Via Benzinga
NLS Pharmaceutics Successfully Appeals Nasdaq Delisting Notice
Via ACCESSWIRE
NLS Pharmaceutics Provides Open Label Extension Study Update for Quilience(R) (Mazindol ER) in the Treatment of Narcolepsy
Via ACCESSWIRE
U.S. FDA Grants Orphan Drug Designation (ODD) for Quilience(R) (Mazindol ER) for the Treatment of Idiopathic Hypersomnia (IH)
Via ACCESSWIRE
Why Harsco Shares Surged Over 22%; Here Are 80 Biggest Movers From Yesterday
Via Benzinga
Why Huntington Bancshares Shares Surged Around 10%; Here Are 72 Biggest Movers From Friday
Via Benzinga
Why Boston Beer Shares Are Trading Higher? Here Are 52 Stocks Moving In Friday's Mid-Day Session
Via Benzinga
Why Laser Photonics Shares Surged By Around 19%; Here Are 70 Biggest Movers From Friday
Via Benzinga
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.